Commentary on BPH and Public Health-Have We Lost the Forest Through the Trees?

Journal of Urology

Volumn 179, Issue 5 SUPPL., 2008, Pages

  Parsons, J Kellogg ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CLINICAL FEATURE; EDITORIAL; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PUBLIC HEALTH SERVICE; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; HUMANS; MALE; MIDDLE AGED; MORBIDITY; PROGNOSIS; PROSTATIC HYPERPLASIA; PUBLIC HEALTH; UNITED STATES;

EID: 41649118736     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.03.014     Document Type: Editorial

References (5)

1. Centers for Disease Control. Public Health and Aging: Trends in Aging-United States and Worldwide (2003). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5206a2.htm
2. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
3. Parsons J.K., Bergstrom J., and Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101 (2008) 313
4. Parsons J.K., Carter H.B., Partin A.W., Windham B.G., Metter E.J., Ferrucci L., et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91 (2006) 2562
5. Kristal A.R., Arnold K.B., Schenk J.M., Neuhouser M.L., Goodman P., Penson D.F., et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol (2008) Epub ahead of print.